BenParkMDPhD(He/Him)

PubMed

• Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations.
  Adam X Miranda, Justin Kemp, Brad A Davidson, Sara Erika Bellomo, Verda E Miranda
  BMC Genomics. 2024-05-27
• Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
  Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia
  Cancer. 2024-05-15
• 4 citations
  An in vitro CRISPR screen of cell-free DNA identifies apoptosis as the primary mediator of cell-free DNA release.
  Brad A Davidson, Adam X Miranda, Sarah C Reed, Riley E Bergman, Justin D J Kemp
  Communications Biology. 2024-04-10

Journal Articles

• High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients  
  Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B., Breast Cancer Res Treat, 1/1/2018
• PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity  
  Croessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, Cochran RL, Dalton WB, Erlanger B, Cravero K, Button B, Kyker-Snowman K, Hurley PJ, Lauring J, Park BH, Breast Cancer Res Treat, 1/1/2017
• Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board  
  Dalton B, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson E, S..., JCO Precision Oncology, 1/1/2017
• A single nucleotide polymorphism leading to a false allelic fraction by droplet digital PCR  
  Christenson ES, Dalton WB, Chu D, Waters I, Cravero K, Zabransky DJ, DeZern A, Park BH., Clin. Chem., 1/1/2017
• AACR Project GENIE: Powering Precision Medicine through an International Consortium  
  Cancer Discovery, 1/1/2017
• Liquid Biopsy: Unlocking the Potentials of Cell Free DNA  
  Chu D and Park BH., Virchows Archives., 1/1/2017
• Frequent BRAF V600E mutations in metanephric stromal tumor  
  Argani P, Lee J, Netto GJ, Zheng G, Tseh-Lin M, Park BH, Am J Surg Path, 1/1/2016
• Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercis...  
  VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P., Am J Surg Pathol., 1/1/2016
• A polycythemia vera JAK2 mutation masquerading as a germline cancer mutation in a patient with duodenal cancer  
  Lee J, Axilbund J, Dalton BD, Laheru D, Watkins S, Chu D, Cravero K, Button B, Kyker-Snowman K, Waters I, Gocke C, Lauring J and Park BH., The Journal of the National Comprehensive Cancer Network, 1/1/2016
• Circulating Tumor DNA�the Potential of Liquid Biopsies  
  Cravero K and Park BH, Curr Breast Cancer Rep, 1/1/2016
• Use of cell free DNA in breast oncology  
  Canzoniero JV and Park BH., BBA - Reviews on Cancer., 1/1/2016
• ESR1 mutations: Pi�ce de r�sistance  
  Button B and Park BH., Genes and Diseases, 1/1/2016
• Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramati...  
  VandenBussche C, Cimino-Mathews A, Park BH, Emens LA, TsangarisTN, Argani P., Am.J.Surg.Path., 1/1/2015
• Activating PIK3CA mutations induce an EGFR/ERK paracrine signaling axis in basal-like breast cancer  
  Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola N, Silva GO, Patel P, Brantley-Siede..., Molecular & Cellular Proteomics., 1/1/2015
• Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA  
  Valda Toro P, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, Cravero K, Chu D, Zabransky DJ, Wong HY, Croessmann S, Parsons H, Hurley PJ, Lauring J, Park BH, Clin. Biochem., 1/1/2015
• Use of Biomarkers for the Assessment of Chemotherapy-induced Cardiac Toxicity  
  Christenson E., James T., Agrawal V., Park BH, Clinical Biochemistry, 1/1/2015
• Gene mutation profiling of breast cancers for clinical decision making: drivers and passengers in the cart before the horse  
  Stearns V and Park BH, JAMA Oncology, 1/1/2015
• A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the miR-183-96-182 cluster  
  Li XL, Hara T, Choi Y, Subramanian M, Francis P, Bilke S, Walker RL, Pineda M, Zhu Y, Yan Y, Luo J, Wakefield LM, Brabletz T, Park BH, Sharma S, Chowdhury D, Meltzer P..., MolCellBio., 1/1/2014
• Analysis of BRCA2 loss-of-heterozygosity in tumor tissue using droplet digital PCR  
  Cochran RL, Cravero K, Chu D, Erlanger B, Valda Toro P, Beaver JA, Zabransky DJ, Wong HY, Cidado J, Croessmann S, Parsons H, Kim M, Wheelan SJ, Argani P and Park BH., Human Pathology, 1/1/2014
• Somatic alterations as the basis for resistance to targeted therapies  
  Blair B, Bardelli A, Park BH, The Journal of Pathology, 1/1/2014
• Plasma tumor DNA: On your mark-ers, get set, GO!  
  Wong HY, Park BH., Annals of Translational Medicine, 1/1/2014
• Neural crest transcription factor Sox10 is preferentially expressed in triple negative and metaplastic breast carcinomas  
  Cimino-Mathews A, Subhawong AP, Elwood H, Nassar H, Sharma R, Park BH, Taube J, Illei PB, Argani P., Human Pathology, 1/1/2013
• GATA3 Expression in Breast Carcinoma: Utility in Triple Negative, Sarcomatoid and Metastatic Carcinomas  
  Cimino-Mathews A, Subhawong AP, Elwood H, Nassar H, Sharma R, Park BH, Taube J, Illei PB, Argani P, Human Pathology, 1/1/2013
• A single mutant KRAS allele cooperates with mutant PIK3CA in human epithelial cells to induce transformation  
  Wang GM, Wong HY, Konishi H, Abukhdeir A, Gustin JP, Rosen M, Denmeade S, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Coch..., Cancer Research, 1/1/2013
• mTOR Signaling Feedback Modulates Mammary Epithelial Differentiation and Restrains Invasion Downstream of PTEN Loss  
  Ghosh S, Varela L, Sood A, Park BH, and Lotan T, Cancer Research, 1/1/2013
• Join now to see all

Books/Book Chapters

• Genome Applications in Pathology 
  Chapter: Circulating cell-free DNA for molecular diagnostics and therapeutic monitoring 
  Hunter NB, Beaver JA and Park BH.SpringerEdition 2nd,2018
• Liquid Biopsies in Solid Tumors 
  Chapter: Circulating Free Tumor DNA (ctDNA): The Real-Time Liquid Biopsy 
  Page 105.0 - 118.0Kyker-Snowman K, Park BH.Springer2017
• Digital PCR Applied Protocols, Methods in Molecular Biology 
  Chapter: Detection of Cancer DNA in Plasma of Early Stage Breast Cancer Patients 
  Page 209.0 - 227.0Medford A, Gillani R and Park BH.Editors: Karlin-Neumann and Bizouarn.Springer2017
• Novel Biomarkers in the Continuum of Breast Cancer 
  Chapter: Circulating Plasma Tumor DNA 
  Page 259.0 - 276.0Parsons, H, Beaver J and Park BHEditors: Stearns.Springer2016
• Genome Applications in Biology 
  Chapter: Circulating cell-free DNA for molecular diagnostics and therapeutic monitoring 
  Page 85.0 - 97.0Beaver J, Park BH.Springer2015
• First Aid for the USMLE Step 2, Clinical Knowledge 
  Park BHMcGraw HillEdition Seve,2009
• Encyclopedia of Cancer 
  Chapter: PIK3CA Oncogene 
  Park BHEditors: M. Schwab.SpringerEdition 2nd,2008
• Cancer Medicine 
  Chapter: Tumor Suppressor Genes 
  Park BH, Vogelstein BEditors: Holland and Frei.BC Decker, Hamilton OntarioEdition 6th,2003
• Join now to see all

Abstracts/Posters

• Cell versus Cell-Free Candidate Biomarkers
  Park BH, American Society of Clinical Oncology (ASCO) Annual meeting, Chicago, IL, 1/1/2014

Lectures

• Breast Cancer Mutations as Diagnostic and Therapeutic Targets for Therapy 
  University of North Carolina, Chapel Hill, NC - 1/1/2019
• Precision Breast Oncology: Genes to Drugs 
  The Mayan Riveria, Mexico - 1/1/2019
• Mutations in breast cancer as diagnostic and therapeutic targets 
  Baltimore, MD - 1/1/2018
• Germline v Somatic testing and the importance of Molecular Tumor Boards 
  White Oak, MD - 1/1/2018
• Breast cancer mutations as targets for therapy 
  Chicago, IL - 1/1/2018
• Breast cancer mutations as therapeutic and diagnostic targets 
  Moffitt Cancer Center, Tampa Bay, FL - 1/1/2018
• Circulating Tumor DNA to Guide Therapies for Early Stage Breast Cancer 
  Johns Hopkins School of Medicine, Baltimore, MD - 1/1/2018
• Research Integrity Colloquium 
  1/1/2018
• Precision Oncology: Using Science to Treat Patients 
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD - 1/1/2018
• Spliceosome mutations as targets for breast cancer therapy 
  Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD - 1/1/2018
• Targeting rare spliceosome mutations in breast cancer 
  Baltimore, MD - 1/1/2018
• Breast Cancer Research Foundation Prevention Think Tank, Biomarkers of Risk 
  New York, NY - 1/1/2018
• Precision Oncology: Using Science and Technology to Treat Individual Cancer Patients 
  Cambridge, MD - 1/1/2018
• Tumor Heterogeneity: Mixing things up. 
  Curacao - 1/1/2018
• Liquid Biopsies for Breast Cancer 
  Hamilton, Bermuda - 1/1/2018
• Circulating plasma tumor DNA as biomarkers for breast cancer therapy 
  University of Maryland, Baltimore, MD - 1/1/2017
• Revolutionizing cancer diagnosis 
  Bethesda MD. - 1/1/2017
• Circulating cell-free plasma tumor DNA: Applications for Breast Oncology 
  University of Washington, Seattle, WA - 1/1/2017
• Precision therapy for breast cancer: Ending overtreatment and undertreatment. 
  University of Washington, Seattle, WA - 1/1/2017
• Targeting spliceosome mutations for breast cancer therapy 
  Dallas, TX - 1/1/2017
• Breast cancer mutations as diagnostic and therapeutic targets 
  New York, NY - 1/1/2017
• Breast cancer mutations for diagnostic and therapeutic applications 
  Vanderbilt Ingram Cancer Center, Nashville, TN, 2017; University of Michigan Comprehensive Cancer Ce - 1/1/2017
• Liquid biopsies for metastatic breast cancer 
  Houston, TX, 2017; New York, NY, 2017 - 1/1/2017
• Liquid biopsies to guide clinical decision in breast cancer 
  Komen of Maryland, Baltimore, MD - 1/1/2017
• Circulating plasma tumor DNA: Biomarkers for Precision Breast Oncology 
  Salisbury, MD - 1/1/2017
• Join now to see all

Other

• Guide 2 Chemo 
  Shockney L, Park BH
  http://www.guide2chemo.com/
  1/1/2009
• Mutations in cancer cells 
  Avon Foundation Breast Care Fund Presentation
  1/1/2007